Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to diagnose Idiopathic Nephrotic Syndrome (INS) without the need for a kidney biopsy, which is a procedure that can be invasive and carries risks, especially during acute illness. Researchers are focusing on finding specific antibodies in the blood that can help distinguish between different types of kidney problems that cause INS. They have developed a scoring system called the SNIT, which uses common clinical and laboratory information to help identify INS in patients who test negative for the main antibody linked to one type of nephrotic syndrome.

To be eligible for this study, participants must be 18 years or older and hospitalized for their first episode of nephrotic syndrome, which means they have high levels of protein in their urine and low albumin levels in their blood. Additionally, they must not have certain known kidney diseases like lupus nephropathy or IgA nephropathy. If you participate, you can expect to help researchers validate this new diagnostic tool, which could make diagnosing kidney issues safer and more accurate for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years and older
• • Hospitalized for a first episode of nephrotic syndrome (proteinuria greater than 3g/g and albumin level \< 30g/L)
• • Negative anti-PLA2r antibodies in the blood
• • Requirement for a renal biopsy for diagnostic purposes
• Exclusion Criteria:
• • Patients with known lupus nephropathy (prior to the current episode)
• • Patients with known IgA nephropathy (prior to the current episode)